Introduction
Several studies have shown that the increased survival of primary acute myeloid leukaemia (AML) blasts in vitro is predictive of a poor response to remission-induction chemotherapy. [1] [2] [3] It therefore follows that a study of the biology of apoptosis-resistant primary AML clones could provide vital insights into the mechanisms of chemoresistance. An increased understanding of the molecules and pathways involved in apoptosis-resistance would have important implications in the design of new treatments for AML.
Although many factors have been studied which contribute to chemoresistance in model systems, very few have been identified that are unequivocally associated with treatment failure in AML. Several studies have demonstrated a role for interleukin-1 (IL-1) in leukaemic cell growth [4] [5] [6] [7] and it has been demonstrated that some AML clones can proliferate in vitro in the absence of exogenous growth factors. These cells have the ability to produce IL-1, which regulates autonomous growth. [8] [9] [10] More recently, in other systems, the binding of IL-1 to its receptor was found to activate a phosphatidylinositol 3-OH kinase (PI-3 kinase)-mediated survival pathway, 11 as well as a ceramide-metabolising pathway. 12 Therefore, although it is well documented that IL-1 is produced by AML cells and has a role in AML cell growth, 13 its possible function in survival, and hence apoptosis-resistance, has not yet been examined in this disease. In the present study, one of our aims was to establish whether there is an association between AML blast cell survival in vitro and autocrine production of IL-1 and whether the exogenous addition of IL-1 prolongs in vitro survival. In addition, we have investigated whether the production of and responsiveness to IL-1 and subsequent signalling via the IL-1 receptor-associated kinase (IRAK), PI-3 kinase (PI-3K) or sphingosine kinase might underpin the apoptosis-resistant phenotype in AML. Figure 1 summarizes the IL-1 survival signalling pathways that we hypothesize to be relevant in AML. The PI-3 kinase/Akt signalling pathway is activated in response to growth factors and promotes cell survival in many systems. [14] [15] [16] Akt, also known as serine-threonine protein kinase B (PKB), mediates the PI-3K survival signal and is activated upon phosphorylation at its Thr-308 and Ser-473 residues. 14, 15, 17 Activated Akt phosphorylates and so inactivates the proapoptotic protein Bad. This results in cell survival. Cell death occurs when dephosphorylated Bad interacts with and inactivates prosurvival proteins such as Bcl-2 and Bcl-X L . 14, 18 Activation of the PI-3 kinase/Akt signalling pathway has been implicated in the IL-1-induced cell proliferation 19 and survival 20 of AML blast cells. The latter study showed that Akt is constitutively activated in a high proportion of AML blast cells, although the mechanism of activation was not reported. These findings have therefore prompted us to investigate whether IL-1b is responsible for Akt activation.
PI-3K can activate protein kinase C (PKC), which mediates the phosphorylation of Bcl-2, resulting in its antiapoptotic function. 17, 21 Protein phosphatase (PP2A) is a protein serine/ threonine phosphatase that is activated by proapoptotic ceramide and can inhibit the activity of survival factors such as PKC, Akt and Bcl-2.
22 PP2A dephosphorylates Bcl-2 and so inhibits its antiapoptotic function. 23 IL-1b might therefore mediate Bcl-2 phosphorylation via activation of both PI-3K and ceramidase. We have therefore investigated the phosphorylation of Bcl-2 in response to exogenous IL-1b.
More recently, IL-1 has been found to activate neutral ceramidase via the p38 MAPK pathway. 12 In addition, intracellular levels of ceramide have been associated with chemoresistance in AML, with chemoresistant AML patient cells exhibiting lower levels of in vitro ceramide than chemosensitive cells. 24 Ceramidase mediates the first step in the pathway through which proapoptotic ceramide 25 is converted into the downstream growth and survival promoting metabolite, sphingosine-1-phosphate (S-1-P). [26] [27] [28] [29] [30] Ceramidase hydrolyses ceramide to sphingosine and free fatty acid and sphingosine is further phosphorylated to form S-I-P, through the action of sphingosine kinase. 24 S-1-P inhibition is known to be toxic to primary leukaemic cells, 31 and so we were interested in exploring the role of IL-1 in this ceramide-metabolising pathway in AML.
The transcription factor, nuclear factor-kB (NF-kB), also has a role in cell survival 32 and is activated by IL-1. 33, 34 It has been suggested that this IL-1 induced activation of NF-kB involves two independent pathways. 11 One pathway is initiated when PI-3K is recruited to the IL-1 receptor (IL-1R 1 ), following IL-1 stimulation. 11 The other pathway is initiated when IRAK binds to the IL-1 receptor components. 11, 35, 36 It has recently been shown that IL-1b induces activation of NF-kB, which mediates the proliferation of AML cell lines 33, 34 and that NF-kB is constitutively activated in primitive human AML cells. 37 This is relevant, since if the production of IL-1 by AML blasts and their subsequent survival is underpinned by NF-kB activation, then NF-kB inhibition should lead to the downregulation of IL-1b and impaired survival in AML blasts. We therefore investigated whether IL-1b upregulates NF-kB activation in AML patient blasts.
Materials and methods

Reagents
7-Amino-actinomycin D (7-AAD), N,N-dimethylsphingosine (DMS), RPMI 1640, Hepes buffer, endotoxin free, fraction V bovine serum albumin (BSA), phosphoserine, hydroxyurea, L-glutamine and penicillin/streptomycin were from Sigma, Poole, England. DMS was initially dissolved in ethanol and further dissolved in 1% BSA to 500 mM and stored at À201C. Foetal calf serum (FCS) was from First Link (Birmingham, England) and was heat inactivated for 1 h at 561C. Recombinant human Interleukin-1b (rhIL-1b) was from Biosource International (CA, USA). Interleukin -1 actually describes two polypeptide hormones, IL-1a and IL-1b, 38, 39 which provoke similar biological responses upon binding to the IL-1 receptor. 10 However, since IL-1b is the predominant form of IL-1, that is what was used in the present study. Wortmannin and AG 126 (Calbiochem, Nottingham, England) were dissolved in DMSO and stored at À201C. Carboxyfluorescein diacetate, succinimidyl ester (CFSE) was from Molecular Probes (Cambridge Bioscience, Cambridge, England). It was reconstituted in DMSO to 10 mM and further dilutions were made in RPMI 1640. Affinity purified antibody to phosphorylated Bcl-2 (P-Bcl-2-ser 70) (cat. no. sc-16647) and control goat immunoglobulins were from Santa Cruz Biotechnology (UK distributer: Autogen Bioclear UK Ltd., Mile Elm, Calne, UK). FITC-conjugated anti-goat secondary antibody was from Dako (Ely, Cambridgeshire, England).
AML blast cells
Blood or bone marrow samples from patients with de novo or relapsed primary AML were studied. White cells were isolated using a standard density-gradient/centrifugation method with Histopaque s -1077 (Sigma) and were cryopreserved in liquid nitrogen. As several analyses were planned for each case, samples were chosen in which the original blast cell count was high, that is, 420 Â 10 6 /ml in peripheral blood or 480% blasts in marrow samples. Cryopreserved samples were thawed and rested (90 min at 371C in a 5% CO 2 humidified atmosphere) in RPMI 1640 medium supplemented with 20% FCS, 1% Hepes buffer, 100 U/ml penicillin and 100 mg/ml streptomycin and 2 mmol/l L-glutamine, prior to experimental use. Only samples with a postrest viability 485%, as determined by trypan blue exclusion, were studied. All samples were depleted of T and natural killer cells using CD2-Dynabeads s (Dynal UK Ltd, Bromborough, Wirral, Merseyside, England), at a concentration of 25 ml beads per 10 7 cells, to eliminate a potential source of cytokines that may have affected in vitro blast survival.
Blast cell culture
Primary leukaemic clones (5 Â 10 5 /ml) were incubated in suspension culture (RPMI 1640 with 10% FCS, 1% Hepes buffer, 100 U/ml penicillin and 100 mg/ml streptomycin and 2 mmol/l L-glutamine) for 48 h in a 5% CO 2 humidified atmosphere. Cells were incubated at 10 6 /ml in the interleukin1b secretion experiments. Sterile, lidded 'Falcon' tissue culture tubes (Becton Dickinson, Cowley, England) were used.
Flow cytometric determination of apoptosis resistance
In order to determine the number of viable cells remaining after 48-h incubation, cultured cells (200 ml) were removed and mixed with 7-amino-actinomycin D (100 ml at 50 mg/ml) and fixed, normal mononuclear cells (100 ml) that had been stained with FITC-conjugated antibody to CD45 (Becton Dickinson), as previously described. 40 Samples were incubated in the dark (20 min, room temperature), before being analysed using a FACSCalibur flow cytometer with Cellquest software (Becton Dickinson). All tests were set up in duplicate.
We are confident that 7-AAD is a suitable probe for measuring apoptosis, since we have previously shown that the viability of primary AML cells, measured with 7-AAD, is similar to that determined with annexin V after suspension culture. 41, 42 CD45-stained cells that had been fixed in paraformaldehyde were used as an internal standard for the determination of viable cell concentration following culture. Analysis was performed using gating (described in detail elsewhere, 40 to select for CD45-stained cells, viable cells (7-AAD low/forward scatter high) and for total leukaemic populations.
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The percentage spontaneous apoptosis that had occurred in culture was calculated according to the formula: % spontaneous apoptosis IL-1b maintains an apoptosis-resistant phenotype in AML blasts J Turzanski et al was washed out and the cells were rinsed twice before 48-h culture with or without 1 ng/ml rhIL-1b. Additional conditions were set up with or without rhIL-1b containing 0.5 mM hydroxyurea, to block cell proliferation. Cellquest software was used for quantitative analysis of cell proliferation, using the fluorescence of CFSE, with hydroxyurea-treated samples as gating controls.
Interleukin -1b assay
Following 48-h incubation at 10 6 /ml, blast cells were pelleted and the supernatants removed and stored at À801C until required for the enzyme-linked immunosorbent assay (ELISA). Blast cell interleukin-1b secretion was measured using an IL-1b ELISA kit (Pharmingen OptEIAt human IL-1b set), according to the manufacturer's instructions (BD Pharmingen, Cowley, England).
Measurement of phosphorylated Bcl-2-serine 70
Cells were fixed and permeabilized either with the Cell Permeabilization Kit from Harlan Seralab (Oxford Biotechnology, UK), used according to the manufacturer's instructions, or by incubating the cells in 2.5% paraformaldehyde (371C, 10 min) and resuspending in PBS with 1% BSA, 0.1% sodium azide (PBSAA) and 0.1% saponin. Fixed, permeabilized cells (3 Â 10 5 ) were incubated with P-bcl2-ser70 or control antibody at 13 mg/ml (15 min, room temperature). In one experiment, cells were also cultured with P-bcl2-ser70 antibody in the presence of 10 mM phosphoserine. The cells were washed three times and incubated with FITC-labelled secondary antibody for 15 min at room temperature. Following three further washes, fluorescence was analysed by flow cytometry.
Measurement of serine 473 phosphorylated Akt
A modified version of the method developed by Tazzari et al 43 was used. Cells (2 Â 10 5 ) were incubated with or without 1 ng/ ml rhIL-1b for various incubation times. These were washed once with ice-cold PBS, fixed with 2% paraformaldehyde in PBS (371C, 10 min) and then permeabilized with 0.1% saponin in PBSAA (15 min, room temperature). Cells were incubated with 15 mg/ml rabbit polyclonal antibody to phospho-Akt (Ser 473) (New England Biolabs (UK) Ltd., Hitchin, Hertfordshire, England; catalogue # 9277) or a concentration and isotypematched control antibody (rabbit anti-rat, Dako) (1 h, room temperature), washed twice with PBSAA containing 0.1% saponin and incubated with 5/100 ml swine anti-rabbit FITClabelled secondary antibody (Dako, catalogue # F0205) for 30 min at room temperature. The cells were washed with PBSAA and analysed by flow cytometry.
Measurement of NF-kB activation
Activation of NF-kB was assessed using a commercial kit, (TRANSAMt NF-kB p50 kit, Active Motif, Rixensart, Belgium), according to the manufacturer's instructions. This kit specifically measures the DNA binding activity of the p50 subunit of NFkB. 44 T-cell depleted blast cell samples were incubated in duplicate in suspension culture (1 h, 371C) with or without 1 ng/ml rhIL1b. 33 Whole cell protein extracts were prepared and stored at À801C, until required. NF-kB activation was measured using a spectrophotometer (Dynatech, Guernesey, Channel Islands) and was expressed as optical density.
Statistics
Statistics were performed using the Statistical Package for Social Sciences (SPSS) software (Chicago, IL, USA). Owing to the heterogeneity of AML primary clones, nonparametric tests were used throughout. The ELISA assay was not sensitive for values below 15.6 pg/ml IL-1b. Therefore, in the analysis of the association between autocrine IL-1b secretion and spontaneous apoptosis, samples with IL-1b secretion below the level of detection were assigned a nominal value of 14 pg/ml.
Results
Association between blast cell survival in vitro and autocrine production of IL-1b
T cell-depleted blast cell samples from 32 patients with AML were maintained in culture medium containing serum, but without added cytokines or stromal cells. The concentration of cells remaining after 48 h was measured flow cytometrically using 7-AAD with fixed, CD45-stained cells as an internal standard and the percentage spontaneous apoptosis was calculated. The culture supernatants from these samples were assayed for autocrine IL-1b secretion. Median IL-1b secretion was 19.7 pg/ml (Table 1 ). There was a significant association between blast cell survival in vitro and autonomous production of IL-1b ( Figure 2 ). Cells that secreted more than 19.7 pg/ml IL1b were significantly more resistant to spontaneous apoptosis than those that produced less than 19.7 pg/ml IL-1b (P ¼ 0.008, using a two-sided Mann-Whitney U test).
Exogenous rhIL-1b enhances survival in AML cells
Leukaemic transformation is often accompanied by the acquired ability to produce growth factors. 45 Previous work in our laboratory has shown that IL-1 supports clonogenic growth in most AML samples 8 and that leukaemic clones that can proliferate in vitro without added growth factors are themselves producers of IL-1. 9 To determine whether IL-1b does promote survival in AML blasts, we added 1 ng/ml rhIL-1b (optimized concentration) to 29 blast cell samples that were maintained in suspension culture. Cell survival was assessed after 48 h. Table 1 shows that the addition of rhIL-1b enhanced cell survival in 25 out of 29 cases studied (median increase was 39.5%). The observed increase in survival was found to be significant (P ¼ 0.0001, using a two-sided Wilcoxon signed-ranks test). Three samples showed a decrease in survival with rhIL-1b and one sample remained unaffected.
Exogenous rhIL-1b had little effect on cell proliferation under our culture conditions
Before exploring pathways whereby IL-1b contributes to cell survival in suspension culture, we wished to establish whether survival pathways alone are affected by IL-1b, or whether IL-1b contributed to cell proliferation in suspension culture. Our initial assumption was that IL-1b contributes largely to survival rather than to proliferation. This is because, in the 29 samples studied for in vitro survival with or without rhIL-1b, only two were found to have a concentration greater than 5 Â 10 5 cells/ml (the starting concentration) after 48 h without exogenous rhIL1b. Only three samples exceeded the starting concentration following culture with exogenous rhIL-1b. Therefore, there was net cell death in the majority of samples. It was possible, however, that the cells were still proliferating under these conditions, even if the proliferation was masked by cell death. To assess this possibility, we used two samples with high IL-1b secretion, three samples with a substantially higher cell concentration after culture in the presence compared to the absence of exogenous rhIL-1b, and one (patient 23), which both secreted IL-1b and responded strongly to exogenous rhIL-1b. These samples were primed with the membrane dye CFSE, which can be used to track cell proliferation. The dye is rapidly taken up and retained by cells, so that a decrease in dye fluorescence following a period of in vitro culture corresponds to the sharing of retained dye between daughter cells. These assays showed that proliferation only increased in one out of six samples studied (Table 2 and Figure 3 ). In this sample, an extra 5% of cells had proliferated in the presence of rhIL-1b. In several cases, the cell concentration had been over 100% higher in the presence, compared to the absence of IL-1b (Table 3) . It is therefore safe to conclude that the main effect of rhIL-1b on AML blasts in suspension culture, with no other added cytokines/growth factors, is on survival rather than on proliferation.
Interleukin-1b activates survival pathways which can be inhibited by wortmannin, AG 126 and
Several signalling kinases have been implicated in the survival of leukaemic cells 46 and, as referenced in the introduction, IL-1 receptor ligation can trigger PI-3 kinase, IRAK and ceramidase activation. Inhibitors of all three of these survival pathways were therefore used to determine their effects upon AML blast cell survival. The PI-3 kinase inhibitor, wortmannin, is a microbial product with established antitumour activity. 47 AG 126 is a putative tyrosine kinase inhibitor of IRAK 48 and to our knowledge, other molecular targets have not been described. N 0 N 0 -dimethylsphingosine (DMS) is an inhibitor of sphingosine kinase, which was first identified as a naturally occurring sphingosine metabolite. DMS inhibits the metabolism of ceramidase-generated sphingosine into the survival-promoting sphingosine-1-phosphate, 30 and has been shown to be toxic to AML blasts in vitro. 31 This inhibitor also inhibits purified PKC 49 but does not appear to inhibit PKC in intact cells. T-cell depleted blast cells from 29 AML patients were maintained in suspension culture (5 Â 10 5 /ml) with or without rhIL-1b (1 ng/ml) for 48 h and the concentration of viable cells remaining was determined by flow cytometry. In vitro cell survival with rhIL-1b was enhanced in 25/29 samples. This increase in survival was significant (P ¼ 0.0001, using a two-sided Wilcoxon signed-ranks test). Spontaneous apoptosis (%) of blast cells at 10 6 /ml was measured, after 48 h, by a flow cytometric technique and the concentration of secreted IL-1b in the culture supernatant was determined by ELISA. ND ¼ not done.
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An apoptosis-sensitive sample (patient 2) with a strong survival response to exogenous IL-1b was selected to study the IL-1b specificity and additive effects of the inhibitors. Cells (5 Â 10 5 /ml) were treated with 1 ng/ml rhIL-1b alone and in combination with wortmannin (1 mM), AG126 (5mM) and DMS (5mM) for 48 h. Figure 4 shows that all three inhibitors downmodulated the rhIL-1b-mediated increase in blast cell survival in 48-h culture. Furthermore, we concluded that each inhibitor acted upon a different pathway, since each combination of two inhibitors had a greater effect than single inhibitors, and only the combination of all three inhibitors eliminated viable leukaemic blasts. The inset to Figure 4 shows the effect of the inhibitors when added alone, without rhIL-1b. 
Figure 2
Interleukin-1b production is associated with an apoptosis-resistant phenotype. Blast cell samples from AML patients were T-cell depleted and maintained (10 6 /ml) in suspension culture containing 10% FCS, but without stromal cells or added cytokines. The % spontaneous apoptosis was measured after 48 h by a flow cytometric technique and the concentration of secreted IL-1b in the culture supernatant was determined by ELISA. Cells that secreted 419.7 pg/ml IL-1b were significantly more resistant to spontaneous apoptosis than those that secreted o19.7 pg/ml IL-1b (P ¼ 0.008, n ¼ 32, using a Mann-Whitney U test with two-sided significance). Blast cells were primed with CFSE and incubated for 24 h in the absence (a) or presence (b) of rhIL-1b. Viable cell number was assessed by flow cytometry as described. IL-1b affects survival in AML cells through multiple pathways. We therefore sought to identify downstream targets, which might contribute to cell survival. Protein kinase C (PKC) mediates phosphorylation of Bcl-2 21 and therefore IL-1b might act on Bcl-2 phosphorylation via activation of PI-3 kinase and, subsequently, PKC. Moreover, ceramide induces the dephosphorylation of Bcl-2, 22 so IL-1b may also increase phosphorylation of Bcl-2 by activating the ceramidase pathway. rhIL-1b-mediated Bcl-2-serine 70 phosphorylation was measured in patient sample 2 by flow cytometry. rhIL-1b induced a transient increase in Bcl-2 serine 70 phosphorylation (Table 4) , which peaked within a few minutes and then declined, such that measurements at 30 min, 1, 3 and 24 h were similar to baseline values. Phosphorylation of serine 473 Akt in response to exogenous rhIL-1b was also monitored over time. Table 5 shows that there was a transient increase in phosphorylated serine 473 Akt above baseline values following stimulation with rhIL-1b. This increase was small and statistically nonsignificant, but consistent in four repeat experiments. Phosphorylation had peaked by 15 min and then decreased. Mean increase in phosphorylated AKT was 14.42% at 15 min.
Effect of rhIL-1b upon NF-kB activation
There have been recent reports of constitutive NF-kB activation in AML blasts. 37 In addition, it has been demonstrated that IL-1b induces activation of NF-kB 10 and that AML cell proliferation is mediated through the induction of NF-kB in AML cell lines. 33 NF-kB activation can occur downstream of IRAK (Figure 1) . Moreover, the IRAK inhibitor, AG126, was found to reduce the cell concentration in rhIL-1b-treated suspension culture blasts from patient 2 by 28% (Figure 4) . We therefore investigated whether exogenous rhIL-1b induced NF-kB activation in cells from this patient. T-cell depleted blasts were incubated with rhIL-1b (1 ng/ml) for 1 h and whole cell extracts were tested for NF-kB activation. NF-kB p50 binding was found to increase by 11.5% (Table 6 ). This small increase could, however, be due to random experimental variation (see below).
Activation of the PI-3 kinase and ceramidase pathways are common to all cases studied but the IRAK/NF-kB pathway is less commonly activated
The above investigation of pathways mediating IL-1b-induced survival was performed on a single primary sample (patient 2) that was selected because (1) it produced no IL-1b (2) it showed a very large increase in survival in response to exogenous rhIL1b (3) exogenous rhIL-1b did not induce an increase in proliferation and (4) several aliquots of the sample were available to us. We could, therefore, unambiguously look at the effects of exogenous rhIL-1b on survival in this sample. However, we also investigated whether our results could be generalised to other AML cases and whether autonomous producers of IL-1b use the same signalling pathways as nonsecretors. Nine blast cell samples were treated with wortmannin (1mM), AG126 (5mM) or DMS (5mM) for 48 h. Table 3 shows that wortmannin (median inhibition was 65%) and DMS (median inhibition was 78%) inhibited survival in all nine cases. The degree of survival inhibition was not associated with the capacity to autonomously produce IL-1b. AG126 was less effective at inhibiting survival (median inhibition was 13%). We also further investigated activation of NF-kB p50 binding. Tcell depleted blast cell samples from 15 patients with AML were incubated for 1 h with rhIL-1b (1 ng/ml) and whole cell extracts were tested for NF-kB activation. Changes varied from a 12.5% decrease to a 31.5% increase. Taking a cut-off point of 715%, to account for random experimental variation, five out of the 15 samples showed an increase in NF-kB p50 binding with rhIL-1b (Table 6 ). These data indicate that rhIL-1b activates NF-kB in some, but not all cases of AML. There was no correlation between the activation of NF-kB in response to exogenous rhIL1b and the enhancement of a clone's in vitro survival in response to this cytokine.
Discussion
In this study, we have found an association between AML blast cell survival and autocrine production of IL-1b in 48-h culture. It has previously been shown that endogenous IL-1 regulates the autocrine production of GM-CSF, and hence proliferation, in some AML blasts, 7, 8 but, to our knowledge, this is the first time that autocrine production of IL-1b has been linked with blast cell survival, and hence apoptosis resistance, in suspension culture. The relevance of IL-1 in mediating apoptosis resistance was reinforced by our finding IL-1b maintains an apoptosis-resistant phenotype in AML blasts J Turzanski et al that exogenous addition of rhIL-1b significantly enhanced survival in 25 out of 29 blast cell samples maintained in 48-h suspension culture. Interestingly, rhIL-1b decreased survival in three of the clones tested. This demonstrates the heterogeneous nature of AML and the potential importance of understanding survival signalling pathways, so that specific treatment regimens can be applied for specific phenotypes of the disease. Exogenous rhIL-1b had little effect upon cell proliferation, indicating that under our culture conditions, rhIL-1b was mainly acting upon survival and not upon proliferative pathways.
The above findings prompted us to try to deduce which molecules and signalling pathways may be underpinning an IL-1b-mediated survival pathway and our results indicated that pathways mediated by ceramidase, PI3kinase and IRAK were all involved, to varying extents. PI-3 kinase plays a critical role in cell survival. A downstream target of PI-3 kinase is Akt, which, upon phosphorylation, has the capacity to inactivate proapoptotic proteins such as Bad and caspase-9, and to suppress the translocation of Bax to the mitochondrion. In one study, a high proportion of AML samples were found to constitutively contain phosphorylated Akt, although the mechanism of activation was not investigated. 20 In addition, a very recent investigation has shown that inhibition of PI-3 kinase results in dephosphorylation of both Akt and BAD, leading to apoptosis in AML cells. 51 We have found that exogenous rhIL-1b mediated a small, transient phosphorylation of serine Akt in blast cells from patient 2. Phosphorylation of Bcl-2 is required for its death suppressor signalling activity. 52 Protein kinase C (PKC) mediates phosphorylation of Bcl-2 21 and so IL-1b might induce Bcl-2 phosphorylation via the activation Table 4 Phosphorylation of bcl-2-serine 70 in response to exogenous rhIL-1b /ml) were incubated in suspension culture with 1 ng/ml IL-1b for the given lengths of time. Bcl-2-serine 70 phosphorylation was determined by antibody staining and flow cytometry. D: Kolmogorov-Smirnov D statistic for fluorescence intensity distribution at the various time points when compared with the baseline value. All D values of 0.08 and above were statistically significant at Po0.001. /ml) were incubated in suspension culture with 1 ng/ml IL-1b for the given lengths of time. Akt phosphorylation was determined by antibody staining and flow cytometry. D: Kolmogorov-Smirnov D statistic for fluorescence intensity distribution at the various time points when compared with the baseline value. All D values of 0.08 and above were statistically significant at Po0.001.
Table 6
Effect of exogenous rhIL-1b upon NF-kB p50 subunit binding T-cell depleted blast cell samples from 15 patients with AML were incubated for 1 h with 1 ng/ml rhIL-1b and the whole cell protein lysates were tested for NF-kB activation.
IL-1b maintains an apoptosis-resistant phenotype in AML blasts J Turzanski et al of PI-3 kinase and PKC (Figure 1) . We found that rhIL-1b induced a transient increase in bcl-2 serine 70 phosphorylation in blast cells from patient 2. A similar transient early phosphorylation of Bcl-2 has been observed following treatment with IL-3 21 and, to the best of our knowledge, phosphorylation of Bcl-2 following treatment with rhIL-1b has not previously been reported. Previous work in our laboratory did not find a significant correlation between the expression of total cellular Bcl-2 and IL-1b secretion in AML blasts and exogenous rhIL-1b failed to upregulate total bcl-2 (unpublished observations). The phosphorylated form of Bcl-2 therefore appears to be important in IL-1b-mediated survival pathways in AML.
Bcl-2 dephosphorylation can occur through ceramidemediated activation of PP2A.
23 IL1 metabolises cellular ceramide through activation of ceramidase, 12 and may therefore be involved in activation of Bcl-2 through dephosphorylation induced by ceramide depletion. The fact that DMS inhibited both IL-1-dependent and IL-1-independent survival in our experiments, suggests that this pathway may be important in AML and merits closer investigation.
Inhibition mediated by IRAK was 5% or less in 3/9 cases. Likewise, NF-kB was not activated in all cases. The exogenous addition of rhIL-1b has previously been shown to activate NF-kB in AML cell lines, where the IL-1-activated complex consisted of both p50 and p65 subunits. 33 , 34 We investigated activation of NF-kB p50 binding and found that rhIL-1b activated NF-kB in some, but not all cases of primary AML. In addition, there was no correlation between the activation of NFkB in response to exogenous rhIL-1b and the enhancement of in vitro survival with this cytokine. These data suggest that NF-kB is not the major transcription factor mediating IL-1-induced survival pathways, or that additional factors are needed to activate NF-kB. 11 In conclusion, we have found that IL-1b secretion is associated with an apoptosis-resistant phenotype in AML and that inhibitors of IL-1-mediated pathways indicate that more than one signalling pathway is involved in this process. Targeted disruption of these pathways may therefore have a role in the development of new therapies for chemoresistant AML.
